IGC PHARMA, INC. — Earnings
Most recent reported period: FY2025 (Q3) (filed for period ending 2025-09-30) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-09-30 | $191K | ↓-53.6% | $-2M | ↓-6.1% | -1517.8% |
| 2025-06-30 | $328K | ↑+20.6% | $-2M | ↑+32.8% | -580.8% |
| 2025-03-31 | $330K | ↑+11.9% | — | — | — |
| 2024-12-31 | $257K | ↑+26.0% | $-2M | ↑+67.3% | -730.7% |
| 2024-09-30 | $412K | ↑+41.6% | $-2M | ↑+29.9% | -427.2% |
| 2024-06-30 | $272K | ↓-51.0% | $-2M | ↓-14.6% | -880.9% |
| 2024-03-31 | $295K | ↑+39.2% | — | — | — |
| 2023-12-31 | $204K | ↓-38.6% | $-6M | ↓-148.5% | -1469.6% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q3)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 63 quarters
margin trajectory tells the operating-leverage storyGo deeper
IGC Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyIGC Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics